TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.
Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.
XLV’s solution has ...
India's Kumbh Mela, an annual mass Hindu pilgrimage of faith, is unlikely to create a disease outbreak that spreads beyond the country's borders, Dr. Kamran Khan, founder of BioDiaspora, tells Maclean's Magazine's Hannah Hoag in "As millions gather for Kumbh Mela, doctors are watching" (February 11, 2013).
Here's an excerpt (emphasis ours):
Unlike the hajj or the Olympics, the Kumbh Mela is primarily a domestic event. While flights into Saudi Arabia spike to five times normal during the hajj, “with the Kumbh Mela, ...
Dr. Raphael Hofstein, president and CEO of MaRS Innovation, delivered a guest lecture on February 1,2013 at the Revitalizing Medical BioTechnology Commercialization symposium, hosted by Stanford University's NIH Graduate Training Program in Biotechnology.
The one-day event brought academic, venture capital and industry thought leaders together to reflect on the challenges facing technology transfer processes across the biotech industry. (more…)
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. This post coincided with World Cancer Day.
What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy?
Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver ...
Students, faculty and recent alumni with software ideas must apply by Feb. 22
Got a killer software-based idea? Are you passionate about turning that idea into a start-up company?
If you’re a current student, faculty member or recent graduate of the University of Toronto, consider applying to the University of Toronto Early-Stage Technology (UTEST) program.
Applications are now closed. Stay tuned for the third UTEST application call.
Created as a pilot in 2012 to help the U of T community bring their software-based ideas to ...
TORONTO, ON (Jan. 24, 2013) - ScarX Therapeutics, a start-up company commercializing a groundbreaking treatment to dramatically reduce post-operation scarring, is receiving a $250,000 investment from Ontario Centres of Excellence.
This story was covered in Yonge Street Media on January 30, 2013.
ScarX, a topical medication, emerged from Dr. Benjamin Alman's research. Alman, head of orthopedic surgery at the Hospital for Sick Children, is developing his invention in conjunction with MaRS Innovation.
Each year, doctors worldwide perform 240 million surgeries. Currently, no clinically-proven prescription ...